Weiss Multi-Strategy Advisers’s Adaptimmune Therapeutics ADAP Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-40,000	Closed	-$161K	–	568
2019 Q2	$161K	Sell	40,000 -25,000	-38%	-$102K	﹤0.01%	473
2019 Q1	$280K	Hold	65,000	–	–	0.01%	465
2018 Q4	$374K	Sell	65,000 -5,000	-7%	-$36.9K	0.02%	370
2018 Q3	$949K	Sell	70,000 -10,000	-13%	-$105K	0.03%	400
2018 Q2	$950K	Hold	80,000	–	–	0.02%	445
2018 Q1	$898K	Sell	80,000 -20,000	-20%	-$175K	0.03%	431
2017 Q4	$668K	Sell	100,000 -1,000	-1%	-$7.72K	0.02%	476
2017 Q3	$827K	Hold	101,000	–	–	0.03%	394
2017 Q2	$453K	Sell	101,000 -9,000	-8%	-$47K	0.02%	460
2017 Q1	$606K	Hold	110,000	–	–	0.02%	436
2016 Q4	$446K	Buy	110,000 +46,000	+72%	+$221K	0.02%	337
2016 Q3	$451K	Sell	64,000 -1,610	-2%	-$12.3K	0.03%	350
2016 Q2	$535K	Sell	65,610 -44,390	-40%	-$418K	0.04%	319
2016 Q1	$894K	Buy	110,000 +7,000	+7%	+$57.3K	0.04%	347
2015 Q4	$1.24M	Sell	103,000 -14,000	-12%	-$137K	0.09%	220
2015 Q3	$1.4M	Sell	117,000 -3,000	-3%	-$42.4K	0.06%	222
2015 Q2	$2.2M	Buy	+120,000	New	+$2.06M	0.09%	228

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Weiss Multi-Strategy Advisers's ADAP Position: Q3 2019 in Review

Weiss Multi-Strategy Advisers sold out of Adaptimmune Therapeutics (ADAP) in Q3 2019, closing a stake of 40,000 shares — an estimated $161K sold.

Weiss Multi-Strategy Advisers first reported a position in ADAP in Q2 2015 and held it in 17 quarters. The position peaked at $2.2M in Q2 2015. 49 funds tracked by Wall St. Rank hold ADAP as of Q3 2019.

Weiss Multi-Strategy Advisers reported no remaining Adaptimmune Therapeutics position as of Q3 2019 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 40,000 Adaptimmune Therapeutics shares in Q3 2019, an estimated $161K.
Weiss Multi-Strategy Advisers first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 17 quarters.
Weiss Multi-Strategy Advisers's Adaptimmune Therapeutics position peaked at $2.2M in Q2 2015.
49 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2019.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.